GRAIL

918 Total Employees

Year Founded: 2016

View Website

GRAIL Innovation & Technology Culture

GRAIL Employee Perspectives

What types of products or services does your engineering team work on/create? What problem are you solving for customers?

My team works mostly on internal applications, making it easier for various roles to access and modify production data. I also make developer tools. These days, I mostly work on things I identify as having value, whether it’s a front-end engineer, someone in marketing or research. I am passionate about creating.

Tell us about a recent project where your team used AI as a tool. What was it meant to accomplish? How did you use AI to assist?

In the past month, I’ve built new production-grade prototypes for the following: a template management app; an integrated Optical Character Recognition tool; some AI-assistant coding tools; a robust mock-data generation tool; and an automated workflow generation tool. I’ve added command line interfaces for everything I’ve touched. I’ve also been expanding features on existing operations apps. All these things were built with AI, and some of them have AI in their function. I added most of a complex feature to an existing app on Friday alone. I am personally more than 10 times as fast as I was a year ago.

What would that project have looked like if you didn’t have AI as a tool to use? How has AI changed the way you work, in general?

I maybe would have built two of those things, and neither would be nearly as good as it has become already. A number of these projects I would not have even attempted before AI.

Will McKinley, Senior Staff Software Engineer

From the article: Working Smarter, Not Harder: How AI is Empowering These Engineers

What People Are Saying About GRAIL

Product Innovation: Pioneered cfDNA targeted‑methylation plus machine‑learning to detect a multi‑cancer signal and predict tissue of origin, moving beyond mutation‑only assays. Development and validation work indicates very high specificity across dozens of cancers and strong origin prediction in prospective studies.
Investment in R&D: Large, prospective programs (CCGA, PATHFINDER, PATHFINDER 2, SYMPLIFY, NHS‑Galleri) anchor the platform and continue to generate pivotal evidence. A modular PMA has been submitted under Breakthrough Device designation to transition from LDT to full approval.
Innovation Leadership: Helped popularize methylation‑based liquid biopsy and brought a leading MCED test to market while setting evidence and regulatory benchmarks for the field. Ambitious randomized and pragmatic studies, EHR integrations, and global collaborations reinforce category leadership.